OmniActive Health Technologies has launched Fenavari, a proprietary botanical ingredient combining fenugreek and shatavari, as it expands into the women’s health and menopause nutrition market.
The clinically studied extract, the company said in its release, is designed to support women through perimenopause, menopause and post-menopause.
This positions it as a multi-benefit alternative to the fragmented, single-symptom approach which is common in the category.
Clinical backing
Fenavari was evaluated in a randomised, double-blind, placebo-controlled, dose-ranging clinical trial involving 138 women aged 40-60.
According to OmniActive, supplementation with either 300 mg or 500 mg produced improvements in menopause-related symptoms as early as day 14.
By the end of the study, the ingredient was associated with reductions in hot flashes of up to 52% at 300 mg and 61% at 500 mg, while night sweats were reduced by up to 47% and 51%, respectively.
The company also reported benefits relating to sleep quality, mood, occasional feelings of anxiety and sexual wellness.
The study additionally found changes in hormonal markers, including increased estradiol and decreased follicle-stimulating hormone (FSH), which OmniActive says support its positioning around healthy hormonal balance.
The ingredient combines standardised extracts containing 6% shatavarin IV and 4% protodioscin, quantified using HPLC.
OmniActive says its proprietary Integrated Actives technology was used to integrate the two botanical extracts, while AI-based validation was applied during development to investigate their potential mechanisms of action and synergistic effects.
Growing demand, rising expectations
The launch comes as demand for evidence-backed menopause products grows.
A 2026 systematic review of non-soy oral herbal supplements highlighted the increasing interest in non-hormonal approaches, while also noting that the evidence base across herbal menopause products remains inconsistent.
This places greater emphasis on well-designed clinical trials and transparent substantiation for brands seeking to differentiate products in the category.
The opportunity is significant: by 2030, an estimated 1.2 billion women globally are expected to be experiencing menopause, with around 47 million entering the menopausal transition each year.
OmniActive says its own research of nearly 500 women aged 45 and older found that hot flashes, sleep difficulties, night sweats and mood swings were among the most commonly reported concerns, while 63% of respondents said they used natural remedies or over-the-counter products for relief.
Fenavari is hormone-, oestrogen- and soy-free and is manufactured using green solvents.
The firm said the ingredient is expected to become available to formulators later this year, giving supplement brands a new option for developing multi-symptom menopause and women's health formulations.
